Daily Newsletter

08 February 2024

Daily Newsletter

08 February 2024

Telix to acquire QSAM Biosciences for $123.1m

The deal comprises contingent value rights that could see additional payments of $90m.

Vishnu Priyan February 08 2024

Australia-based global biopharmaceutical company Telix Pharmaceuticals has agreed to acquire US-based QSAM Biosciences for $123.1m.

The deal comes after the companies signed a conditional non-binding term sheet for the prospective acquisition.

Telix will also acquire QSAM’s lead investigational drug, Samarium-153-DOTMP (¹⁵³Sm-DOTMP), a new kit-based bone-seeking targeted radiopharmaceutical candidate.

The acquisition terms include an upfront payment of $33.1m (A$50.8m), payable as 4,369,914 ordinary shares of Telix.

The deal also comprises contingent value rights that could see additional payments of $90m on meeting clinical and commercial milestones. These payments may be made in cash and/or shares.

QSAM focuses on the development of therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

Its ¹⁵³Sm-DOTMP for bone cancer has applications in pain management and therapy for bone metastases and osteosarcoma, including for paediatric patients.

It complements Telix’s focus on oncology therapies and has shown promising safety, efficacy and commercial potential in early trials.

The drug also has an improved safety profile, delivery and optimised production.

Recent data suggest ¹⁵³Sm-DOTMP’s efficacy in managing prostate cancer bone metastases pain, addressing a critical unmet need.

Telix also sees potential benefits for patients with metastatic lung and breast cancer, focusing on palliative care and quality of life.

The US Food and Drug Administration (FDA) granted orphan drug and rare paediatric disease designations for ¹⁵³Sm-DOTMP to treat osteosarcoma.

Telix managing director and group CEO Dr Christian Behrenbruch stated: “The acquisition of QSAM provides Telix with an additional near-term therapeutic pipeline asset, further differentiating our innovation position in radiopharmaceuticals and building depth in Telix’s key disease focus areas of urological and musculoskeletal oncology.

“Samarium is a highly optimal radionuclide for treating bone metastases, and the combination of orphan drug designation and rare paediatric disease designation status with Telix’s demonstrated experience in pharmacy-based cold-kit distribution has strong potential for a rapid pathway to commercialisation of this asset.”

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close